BIIB:NSD-Biogen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 281.19

Change

0.00 (0.00)%

Market Cap

USD 41.91B

Volume

1.30M

Avg Analyst Target

USD 406.88 (+44.70%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-17 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

N/A

USD186.58B 41.95 22.57
SNY Sanofi

N/A

USD123.11B 18.29 12.28
AMGN Amgen Inc

N/A

USD118.02B 21.08 12.74
GILD Gilead Sciences Inc

N/A

USD84.80B 16.56 11.46
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
HZNP Horizon Therapeutics Public Li..

N/A

USD25.32B 51.20 36.99
GRFS Grifols S.A

N/A

USD14.00B 25.30 14.77
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
CRXT Clarus Therapeutics Holdings I..

N/A

USD0.12B N/A N/A
CRXTW Clarus Therapeutics Holdings I..

N/A

N/A N/A N/A

ETFs Containing BIIB

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.57B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.79 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.59 %

N/A

USD0.02B
BIOT L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

N/A
OSX2:XETRA Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

N/A

N/A
CEM2:XETRA iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:XETRA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.49B
CEM2:F iShares US Equity Buyback.. 0.00 % 0.55 %

N/A

USD4.53M
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
SPMV:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
MVUS:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
BUYB:PA Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
SBUY:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.04B
BUYB:LSE Invesco Markets III plc -.. 0.00 % 0.39 %

N/A

USD0.07B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.27B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

N/A

USD0.49B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.49B
DQML Reality Shares Fundstrat .. 0.00 % 0.69 %

N/A

USD2.62M
MXDU Nationwide Maximum Divers.. 0.00 % 0.34 %

N/A

USD0.12B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

USD0.54B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
PKW Invesco BuyBack Achievers.. 0.00 % 0.62 %

N/A

USD2.08B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

N/A

USD0.30B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.50 %

N/A

USD0.21B
IBB iShares Biotechnology ETF 0.00 % 0.45 %

N/A

USD10.94B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

N/A

USD0.03B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD9.12M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.84% 57% F 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.84% 57% F 60% D-
Trailing 12 Months  
Capital Gain 0.42% 57% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.42% 43% F 27% F
Trailing 5 Years  
Capital Gain -4.70% 43% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.70% 14% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 1.96% 43% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.96% 43% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 18.82% 43% F 79% C+
Risk Adjusted Return 10.39% 29% F 26% F
Market Capitalization 41.91B 50% F 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.49 57% F 40% F
Price/Book Ratio 3.96 71% C- 35% F
Price / Cash Flow Ratio 9.91 88% B+ 37% F
EV/EBITDA 13.00 57% F 54% F
Management Effectiveness  
Return on Equity 22.14% 57% F 89% B+
Return on Invested Capital 18.47% 89% B+ 88% B+
Return on Assets 7.03% 71% C- 87% B+
Debt to Equity Ratio 69.49% 71% C- 30% F
Technical Ratios  
Short Ratio 2.35 75% C 59% F
Short Percent 1.67% 63% D 65% D
Beta 0.47 43% F 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.